Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.
Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.
复制标题
重新评估复发性胶质母细胞瘤的活检：克里斯托弗·戴维森论坛研究人员的立场声明。
DOI：
10.1093/neuros/nyab063
复制
发表时间：
2021
期刊：
影响因子：
4.8
通讯作者：
Pate
中科院分区：
文献类型：
--
作者：
Nduom,EdjahK;Gephart,MelanieHayden;Chheda,MilanG;Suva,MarioL;Amankulor,Nduka;Battiste,JamesD;Campian,JianL;Dacey,RalphG;Das,Sunit;Fecci,PeterE;Hadjipanayis,ConstantinosG;Hoang,KimberlyB;Jalali,Ali;Orringer,Daniel;Pate
胶质母细胞瘤（GBM）患者需要大胆的新方法来治疗，但进展一直受到相对无法动态跟踪治疗反应，耐药机制，靶向突变的演变和突变负荷变化的阻碍。我们代表一个多学科的学术神经肿瘤学专业人士小组撰写本文，他们于2019年秋季在圣刘易斯的华盛顿大学的克里斯托弗戴维森论坛上会面。我们提出一个戏剧性的，但必要的改变，以推进该领域的GBM患者的常规管理：定期活检复发GBM在假定复发的时间。从这些样本中获得的数据将确定真正的复发与治疗效果，避免成功机会很小的治疗，使临床试验能够进行，并有助于我们对GBM的理解的科学进步。
Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden. We are writing on behalf of a multidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM.